Ozanimod Reduces Serum Neurofilament Light Chain (NfL) and Glial Fibrillary Acidic Protein (GFAP) and Modulates Innate and Adaptive Immunity in Patients with Low-to-Moderate Activity Relapsing-Remitting Multiple Sclerosis
Study Overview The research investigates the effects of ozanimod, an oral medication, on key biomarkers associated with neurodegeneration and inflammation […]
